Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups

被引:3
|
作者
Fukuda, Tatsuya [1 ,2 ,3 ]
Okamoto, Takahiro [1 ]
Fukaishi, Takahiro [4 ]
Kawakami, Akio [5 ]
Tanaka, Makoto [4 ]
Yamada, Tetsuya [3 ]
Monzen, Koshiro [5 ]
机构
[1] Mirraza Shinjuku Tsurukame Clin, Tokyo, Japan
[2] Tokyo Metropolitan Okubo Hosp, Dept Endocrinol & Metab, Tokyo, Japan
[3] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Mol Endocrinol & Metab, Tokyo, Japan
[4] Koganei Tsurukame Clin, Tokyo, Japan
[5] Shinjuku Tsurukame Clin, Tokyo, Japan
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词
metabolic dysfunction-associated steatotic liver disease (MASLD); nonalcoholic fatty liver disease (NAFLD); metabolic and alcohol related/associated liver disease (MetALD); alcohol consumption; weight loss; INDEX; ASIA;
D O I
10.3389/fendo.2024.1392280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The incidence of steatotic liver disease has increased in recent years. Thus, steatotic liver disease is a major public health issue in Japan. This study investigated the association between weight reduction and the remission of metabolic dysfunction-associated steatotic liver disease (MASLD)/Metabolic and alcohol related/associated liver disease (MetALD) in Japanese individuals undergoing health checkups.Methods This retrospective observational study included 8,707 Japanese patients with MASLD/MetALD who underwent health checkups from May 2015 to March 2023. The participants were monitored for its remission at their subsequent visit. MASLD was diagnosed on abdominal ultrasonography and based on the presence of at least one of five metabolic abnormalities. The impact of body mass index (BMI) reduction on MASLD/MetALD remission was assessed via logistic regression analysis and using receiver operating characteristic curves.Results Logistic regression analysis revealed that weight loss was significantly associated with MASLD/MetALD remission. Other factors including exercise habits and reduced alcohol consumption were significant predictors of MASLD/MetALD remission in the overall cohort and in male patients. The optimal BMI reduction cutoff values for MASLD/MetALD remission were 0.9 kg/m2 and 4.0% decrease in the overall cohort, 0.85 kg/m2 and 3.9% decrease in males, and 1.2 kg/m2 and 4.5% decrease in females. In participants with a BMI of 23 kg/m2, the cutoff values were 0.75 kg/m2 and 2.7% BMI reduction.Discussion Weight reduction plays an important role in both MASLD and MetALD remission among Japanese individuals. That is, targeting specific BMI reduction is effective. This underscores the importance of targeted weight management strategies in preventing and managing MASLD/MetALD in the Japanese population.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease
    Wajcman, Dana Ivancovsky
    Byrne, Christopher J.
    Dillon, John F.
    Brennan, Paul N.
    Villota-Rivas, Marcela
    Younossi, Zobair M.
    Allen, Alina M.
    Crespo, Javier
    Gerber, Lynn H.
    Lazarus, Jeffrey V.
    HEPATOLOGY, 2024,
  • [32] Prevalence, incidence, and recovery of metabolic dysfunction-associated steatotic liver disease and associations with weight loss and lipid reduction in a Chinese communitybased cohort
    Xu, Yurou
    Wang, Youyi
    Yao, Xiajing
    Zhao, Qi
    Chen, Bo
    Wang, Na
    Zhang, Tiejun
    Jiang, Yonggen
    Wu, Yiling
    He, Na
    Zhao, Genming
    Sun, Zhongxing
    Liu, Xing
    JOURNAL OF EPIDEMIOLOGY, 2025, 35 (04) : 195 - 205
  • [33] Evaluation of weight loss and improvement of steatotic liver disease using magnetic resonance imaging in patients with metabolic dysfunction associated steatotic liver disease
    Suzuki, Yuichiro
    Maekawa, Shinya
    Osawa, Leona
    Komiyama, Yasuyuki
    Takada, Hitomi
    Muraoka, Masaru
    Sato, Mitsuaki
    Takano, Shinichi
    Morisaka, Hiroyuki
    Onishi, Hiroshi
    Enomoto, Nobuyuki
    HEPATOLOGY RESEARCH, 2025, : 638 - 647
  • [34] Validation of FIB-4 for the diagnosis of liver cirrhosis in metabolic dysfunction-associated steatotic liver disease
    Bera, Chinmay
    Hamdan-Perez, Nashla
    Kosick, Heather Mary-Kathleen
    Shengir, Mohamed
    Sebastiani, Giada
    Patel, Keyur
    CANADIAN LIVER JOURNAL, 2025, 0 (AOP):
  • [35] Association of antinuclear antibody positivity with liver disease severity in pediatric metabolic dysfunction-associated steatotic liver disease
    Kim, Hyun Jin
    Kim, Ju Young
    Lee, Yoo Min
    Hong, Yong Hee
    Kang, Ben
    Choe, Byung-Ho
    Yi, Dae Yong
    Lee, Eun Hye
    Kim, Soon Chul
    Choi, You Jin
    Jang, Hyo-Jeong
    Choi, So Yoon
    FRONTIERS IN PEDIATRICS, 2025, 13
  • [36] Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    Lee, Han Ah
    Moon, Hyeyoung
    Kim, Yuri
    Lee, Jeong Kyong
    Lee, Hye Ah
    Kim, Hwi Young
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2025, 23 (01) : 114 - 123.e13
  • [37] Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease
    Wakabayashi, Shun-Ichi
    Tamaki, Nobuharu
    Kimura, Takefumi
    Umemura, Takeji
    Kurosaki, Masayuki
    Izumi, Namiki
    JOURNAL OF GASTROENTEROLOGY, 2024, 59 (06) : 494 - 503
  • [38] Machine Learning Identifies Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Diabetes Mellitus
    Nabrdalik, Katarzyna
    Kwiendacz, Hanna
    Irlik, Krzysztof
    Hendel, Mirela
    Drozdz, Karolina
    Wijata, Agata M.
    Nalepa, Jakub
    Janota, Oliwia
    Wojcik, Wiktoria
    Gumprecht, Janusz
    Lip, Gregory Y. H.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (08) : 2029 - 2038
  • [39] Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future
    Corrao, Salvatore
    Calvo, Luigi
    Grana, Walter
    Scibetta, Salvatore
    Mirarchi, Luigi
    Amodeo, Simona
    Falcone, Fabio
    Argano, Christiano
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2025, 35 (02)
  • [40] Novel eicosanoid signature in plasma provides diagnostic for metabolic dysfunction-associated steatotic liver disease
    Quehenberger, Oswald
    Armando, Aaron M.
    Cedeno, Tiffany H.
    Loomba, Rohit
    Sanyal, Arun J.
    Dennis, Edward A.
    JOURNAL OF LIPID RESEARCH, 2024, 65 (10)